Breaking the Loss Curse: How Scientist-Entrepreneurs Can Navigate the Perilous Path from Lab to Market

From Zhang Heng’s invention of the seismoscope and Michael Faraday’s development of the electric motor, to the emergence of semiconductors and computers in the 20th century, innovation has flowed continuously through the long river of human history, becoming an enduring force that transcends eras. Today, innovation is a shared global theme, with an increasing number of innovations moving from laboratories to industry, making the commercialization of innovation a defining trend of our time.

However, the journey from inspiration to results, and ultimately to a marketable product, is a protracted and arduous process fraught with challenges. Throughout this entire course, significant R&D investment is required, alongside coexisting risks and opportunities.

For enterprises focused on translating scientific research into commercial applications, early-stage funding challenges are nearly inevitable. This is particularly true for highly innovative, original discoveries that must first be developed into tangible products before they can create new “blue ocean” markets. Such technologies often struggle to find viable monetization pathways in their early stages. Moreover, researchers tend to pursue extreme performance parameters; however, in the context of entrepreneurship, this pursuit translates into increased R&D investment and prolonged development cycles.

On the other hand, since most researchers are first-time entrepreneurs and did not need to consider R&D investment and returns in their previous research, they often experience anxiety over cash burn when managing R&D projects that require calculating return on investment and capital consumption rates. This apprehension discourages them from pursuing breakthroughs in high-barrier application areas.

Therefore, the R&D investment phase is far from easy for scientist entrepreneurs. Innovation requires barriers to entry and substantial investment, yet excessive R&D spending can easily plunge a company into crisis. The delicate balance between R&D and revenue is drawing close attention from scientist entrepreneurs, researchers, and investors alike.

Although scientific research projects also require project initiation assessment and process control, scientists only feel apprehensive about the control of corporate product development processes. The reason lies in the fundamental differences between scientific research and product development.

Scientific research tends to explore the unknown. The fundamental purpose of most scientific research projects is to create knowledge. Correspondingly, the outputs of such projects are primarily in the form of academic papers, patents, and scholarly monographs. Given these characteristics, scientific research projects are typically hosted by universities and research institutions, where researchers initiate and conduct projects based on their own research interests.

During the course of scientific research projects, researchers need to focus more on technical feasibility issues, such as how to achieve material functionality and which chemical groups to introduce.

R&D is highly purpose-driven. For enterprises, the significance of R&D lies in resolving specific technical challenges or developing new products. These projects are often built upon established theoretical foundations. Since the goal of corporate R&D is to deliver products or technologies, the factors considered during project initiation are more complex. Taking new materials as an example, at the R&D stage, research teams must take into account multiple factors, including cost, supply chain, existing market products, regulatory approval status, material risks, and the R&D cycle.

Overall, scientific research focuses on the frontier, while R&D is about practical implementation. It is equally important to emphasize that scientific research forms the foundation of R&D, as the development of any technology requires support from theoretical studies.

When scientific achievements begin to be commercialized, it signifies that the research has transitioned from basic scientific inquiry to the research and development (R&D) stage. At this point, the return on investment must be calculated for any project input. It is precisely for this reason that industry players, academics, and investors have begun to reflect on balancing R&D efforts with financial returns. For startups, the degree of product maturity and the establishment of product milestones will play a decisive role in their future development and growth.

Although the optimal balance point varies for enterprises across different sub-sectors, technical pathways, and capability profiles, it appears to follow discernible patterns when examining the differences and similarities in role positioning, founding teams, and pipeline configurations among companies pursuing diverse development trajectories.

Blindly pursuing high-profile, high-cost strategies is a common pitfall for startups commercializing scientific research outcomes. Although all innovations require the establishment of competitive moats through technological barriers, this does not mean that every product development effort must strive for cutting-edge sophistication and substantial capital investment.

If a company targets the lower-tier markets, where consumers exhibit higher price sensitivity and a lower acceptable price range, cost comparison between its product and competitors’ offerings should be prioritized alongside product reliability. Consequently, such companies should exercise control over R&D expenditures. On the other hand, low-value products typically require substantially higher sales volumes to generate sufficient revenue. Therefore, expanding production capacity is an essential step for enterprises serving these lower-tier markets.

In summary, R&D efforts by companies in lower-tier markets emphasize a comprehensive approach; compared to narrowly defined R&D costs, greater investment may be directed toward supply chain and manufacturing processes.

However, if a company targets tier-3A hospitals with cutting-edge products, its R&D investment strategy differs significantly. This market demands highly innovative products, requiring companies to devote greater effort and capital to the development and even early-stage research phases, while building robust R&D teams. In such scenarios, the balance of financial investment undoubtedly shifts toward the upstream stages of R&D.

It is evident that innovation companies face a certain R&D cycle, whether targeting the lower-tier market or the high-end market. However, in either scenario, sustaining heavy long-term investment is unrealistic for these companies. The balance between R&D and revenue is delicate, and most startups struggle to achieve this equilibrium at the outset. After all, most teams commercializing scientific research lack entrepreneurial experience and must learn and grow through the process of building their businesses.

Therefore, setting the break-even point for most technology transfer companies is a dynamic process that must adapt to changes in the startup lifecycle.

During the initial phase of commercialization, fundamental R&D capabilities must be secured. Judging by the current development patterns in China’s healthcare sector, the overarching theme for both the biotechnology and medical device industries is hard technology and innovation. Consequently, essential upfront investment is indispensable.

In the mid-to-late stages, with the company’s first product already on the market, the decision to either continue expanding R&D investment or accelerate industrialized production to achieve profitability and expand the platform should be tailored to the enterprise’s development needs.

Overall, innovative enterprises in their mid-to-late stages typically have two strategic options: vertical expansion and horizontal research. Vertical expansion involves completing the entire product lifecycle, from research and development to manufacturing and sales. Horizontal research refers to expanding into other product lines based on the foundation of prior research.

For most technology-driven enterprises focused on translating research into commercial applications, horizontal research is an area where their teams excel. Given that R&D teams are a permanent fixture within these companies, they naturally need to continue their work even after achieving initial product success. Through previous product development efforts, these R&D teams have accumulated substantial experience and achieved breakthroughs in foundational technologies. By pursuing horizontal expansion into adjacent products within their relevant professional domains, these companies may be able to deliver more valuable products with relatively lower investment.

In short, if a technology commercialization enterprise has already established a stable R&D team and operational model, and has accumulated a track record of successful R&D experience, then leveraging this expertise to pursue vertical or horizontal product expansion—thereby capitalizing on the firm’s R&D capabilities to generate marginal returns—represents a sound strategy.

In addition to focusing on the overall R&D investment, it is also necessary to consider the efficiency of R&D spending. For instance, an investment of CNY 50 million may yield only one product, whereas an investment of CNY 100 million could generate four to seven products. Although the latter involves a higher total expenditure, its R&D efficiency is actually greater when measured by the average R&D cost per product.

Beyond strategic R&D investment, timely loss mitigation is equally critical. For innovative enterprises, timely loss mitigation does not merely refer to the drastic measure of discontinuing a specific product line in extreme circumstances; rather, it is a dynamic process.

Taking medical devices as an example, founding teams often place high expectations on their products, leading the initial version to encompass an excessive range of clinical needs. However, addressing these needs and implementing the corresponding functionalities require substantial investment, with no guarantee of success even after significant resources have been committed. In such scenarios, it is imperative for the team to make timely adjustments to product definition and development roadmaps during the R&D process.

Timely and dynamic stop-loss measures can often minimize losses to the greatest extent, as delaying pipeline cuts for another 1–3 years would undoubtedly result in even greater losses for the company.

For innovative enterprises, financing is inevitable whether in drug or medical device R&D. Faced with substantial and long-term R&D investments, startups struggle to bridge the funding gap through their own cash flows. In certain highly innovative fields, startups may need to undergo multiple rounds of financing just to achieve basic product milestones. Therefore, it is essential for innovative companies to plan their development milestones rationally.

The pace of R&D is closely intertwined with the rhythm of the capital market. For instance, if Company A reaches a certain milestone ahead of its peers and secures financing first by leveraging this achievement, the influx of capital will undoubtedly accelerate its subsequent R&D progress. If Company A completes its financing one year earlier, the acceleration in its R&D and product launch timelines could extend far beyond just one year within the overall framework.

This represents a chain reaction between capital markets and R&D pacing. By strategically timing fundraising efforts and leveraging the power of capital, companies can significantly accelerate technological accumulation and achieve breakthroughs in research and development. To accomplish this, founding teams must not only possess the ability to proactively generate cash flow but also actively engage with capital markets and maintain precise control over their fundraising rhythm.

The essence of capital is to provide funding and resources for corporate development, yet such support alone cannot fundamentally alter industry cycles or developmental patterns. Moreover, the growth trajectories observed in certain sectors suggest that financing by itself is insufficient to accelerate an industry’s maturation.

In addition to securing external funding, innovative companies must also embrace greater openness to unlock more possibilities. Beyond the linear research approach mentioned earlier, external collaboration is a strategy frequently adopted by innovative enterprises. By leveraging their proprietary technologies and products, these companies can generate revenue streams through open external partnerships. For instance, collaborations between small biopharmaceutical firms and large pharmaceutical companies have become increasingly common in recent years. Moreover, some biopharmaceutical companies have even managed to license their products to overseas markets. Prior to the onset of the biopharmaceutical winter, it was evident that the upfront payments associated with such collaborations were steadily increasing.

Although the returns from these collaborations may still be insufficient to fully cover R&D expenditures, the benefits they generate will, to some extent, help tip the scales of R&D profitability toward greater balance. This is particularly important as capital markets cool down, making it ever more critical to strike a proper balance between inputs and outputs through open collaboration.

For most startups, successfully developing a product based on a core proprietary technology at the outset is already considered an achievement. However, strategic pipeline planning and the team’s ability to manage the R&D pipeline require long-term cultivation; indeed, a pipeline-oriented mindset must be maintained throughout the entire process.

In the early stages of R&D, pipeline strategy is actually in “easy mode”: a team revolves around one or several core technologies to explore directions for technological implementation and possibilities for productization. For scientist-entrepreneurs, they tend to favor blue ocean markets or black ocean domains. However, corporate R&D must ultimately align as closely as possible with market demands. Therefore, we believe that the layout of the first product should possess the following characteristics:

a. Maximize market demand,

b. Minimize the number of similar competing products,

c. Minimize the certification timeline,

d. Minimize R&D investment as much as possible.

Of course, it is nearly impossible to satisfy all four dimensions simultaneously. Therefore, in product planning, it is essential to find a balance and identify a relatively ideal scenario across all aspects for the initial product deployment.

However, after the successful launch of the first product, the pipeline strategy may change significantly. Compared to the R&D phase of the first product, companies can withstand greater pressure and have more room for trial and error, while also accumulating capital, resources, market presence, and reputation. At this stage, companies may have more strength to make additional choices. Therefore, we can see that many companies at this stage, after having several successful pipelines, begin to consider comprehensive brand influence and platform-based expansion.

For biotechnology companies, pipeline strategy requires careful strategic deployment. Some teams adopt a conservative approach to secure success, prioritizing assets with relatively lower risk and higher efficacy or certainty as their first-tier candidates; while others pursue an aggressive strategy, giving precedence to advancing first-in-class products. Based on a comprehensive analysis of numerous cases, we have identified that biotechnology companies primarily consider the following two aspects when structuring their pipelines:

Top of the list is the founding team’s “DNA,” namely a clear understanding of the team’s strengths and weaknesses, as well as its industry competitiveness and differentiated advantages. This “DNA” determines the general direction of the team’s future development.

Next is the barrier to entry in niche industries. For instance, in the field of metabolic diseases such as diabetes and hypertension, existing products have established a remarkably high industry barrier, making it difficult for new products and methods to surpass them. However, if equal effort is invested in industries with slightly lower barriers, there may be a greater chance of exceeding current standards.

On the other hand, industry barriers evolve over time. Once the low-hanging fruit has been harvested, the overall barrier to entry for the entire industry will gradually rise. Therefore, decisions regarding R&D pipeline layout based on barriers in specific sub-sectors must be made within a dynamic context, ensuring both robust industry moats and achievable targets. This perhaps represents yet another aspect of the balancing art inherent in pipeline strategy.

In the process of commercializing scientific research outcomes, it is not necessary for companies to independently overcome every R&D challenge. Outsourcing tasks that do not involve significant technical barriers but are time- and labor-intensive can help enterprises reduce R&D costs and improve efficiency to a certain extent.

Taking medical device inspections as an example, this process may involve rectifications in various details, such as electromagnetic compatibility and material biocompatibility. If the team is unfamiliar with the detailed rules and regulations governing medical devices, it will be difficult to implement the necessary corrections within a short timeframe. In such cases, the advantages of CXO companies become particularly evident. Having handled numerous service cases, CXO teams have accumulated extensive experience and established standardized processes for addressing potential issues associated with different products, along with corresponding corrective measures. The involvement of such professional teams can significantly shorten the cycle for product development and regulatory submission.

Similarly, for technology transfer teams, product filing, registration, and submission for testing are relatively unfamiliar areas. In these processes, entrusting specialized tasks to professionals and actively seeking external assistance may also help achieve the goal of reducing costs and improving efficiency.

Beyond R&D strategy, pipeline layout, and resource synergy, it is also evident that some teams are achieving a certain degree of capital recoupment through low-value-added products. For instance, certain cell therapy and biomaterials companies additionally incubate daily chemical and fast-moving consumer goods (FMCG) products, seeking profitability through these offerings with lower market entry barriers.

It is important to emphasize that any expansion into these other fields must be grounded in the team’s foundational technological expertise. With strict control over both R&D and production costs, such initiatives aim to achieve modest or certain profitability through minimal investment of capital and effort.

Technical professionals are always accustomed to reflecting on their foundational basis for survival. It is precisely for this reason that nearly every researcher planning to translate their achievements into practical applications asks themselves, “What will I rely on to survive?”

From scientific achievements to products, and from R&D to market launch and profitability, enterprises and researchers face numerous challenges. Teams across different companies vary in their backgrounds, core technologies, markets, and product attributes, making it nearly impossible to find a standardized approach to balancing R&D efforts with financial returns. However, by examining historical trends and industry development patterns, it becomes evident that the stages each project must navigate, as well as the difficulties likely to be encountered, share common similarities and characteristics.

For enterprises, their vitality lies in core technologies. Only when core technologies have sufficient barriers can there be enough room for reflection and transformation during difficult times. Most of the time, these challenges are actually tests of a team’s experience, comprehensive capabilities, and mindset. The combination of both—namely, the application and mastery of core technologies, familiarity with industry development patterns, and the ability to leverage external resources—is the key to helping companies find balance and navigate through seemingly impossible cycles.